PO.CL01.21 · 临床研究

用于癌症相关 T 细胞可扩展链配对和免疫表型分析的高通量、96 孔板单细胞 TCR 测序

High-throughput, 96-well plate-based single-cell TCR sequencing for scalable chain-pairing and immunophenotyping of cancer-associated T cells

海报缩略图:用于癌症相关 T 细胞可扩展链配对和免疫表型分析的高通量、96 孔板单细胞 TCR 测序
编号 6515 展板 4 时间 4/21 02:00–05:00 区域 Section 43 主讲 Alex Chenchik, PhD
分会场 Diagnostic Biomarkers 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Alex Chenchik, Tianbing Liu, Dongfang Hu, Kitt Paraiso, Lester Kobzik, Khadija Ghias, Paul Diehl

Cellecta, Inc., Mountain View, CA

摘要 Abstract

中文摘要
我们提出了一种流程精简、基于板的单细胞适应性免疫受体(AIR)分析技术,能够发现并详细表征癌症相关 T 细胞中与疾病相关的 TCR 克隆型。该方法采用可扩展的 96 孔板工作流程,将流式分选的单细胞逐个分离,用于 TCR alpha beta 链以及 36 个免疫表型基因的多重 RT-PCR,随后进行 Illumina NextSeq 测序。该方法利用 MiXCR 和 RCEM 软件流程,提供全长配对 TCR 序列、高分辨率克隆型频率数据以及关键基因表达标志物的谱图。应用于 T 细胞大颗粒淋巴细胞白血病(T-LGL)患者的纵向样本时,该方法在多个时间点识别出优势和罕见克隆型(并进行功能注释),其中包括一例具有单个扩增的细胞毒性效应记忆 T 细胞克隆(n=35 孔,NKG7 和 CCL5 水平升高)的病例。高通量的"迷你批量"配置(约 100 个细胞/孔)可实现约 10,000 个细胞/板的更广泛的库筛选,检测数千个独特的 beta 链和 alpha beta 配对,并有助于识别批量或较低通量方法所遗漏的罕见、疾病相关克隆型。这种快速、经济高效(<$0.10/细胞)的单日工作流程支持大规模转化研究,无需依赖微流控平台或复杂的条形码技术,即可从各种样本中直接获取配对受体和表型特征。该技术显著扩展了免疫基因组学发现和功能性免疫表型分析的能力,使其适用于癌症研究中的生物标志物验证、免疫治疗开发和实时免疫监测。
查看英文原文 English abstract
We present a streamlined, plate-based single-cell adaptive immune receptor (AIR) profiling technology that enables the discovery and detailed characterization of disease-relevant TCR clonotypes in cancer-associated T cells. Using a scalable 96-well plate workflow, flow-sorted single cells are individually isolated for multiplex RT-PCR of TCR alpha beta chains together with 36 immunophenotyping genes, followed by Illumina NextSeq sequencing. The approach leverages MiXCR and RCEM software pipelines to deliver full-length paired TCR sequences, high-resolution clonotype frequency data, and a profile of key gene expression markers. Applied to longitudinal samples from T-cell large granular lymphocytic leukemia (T-LGL) patients, this method identified both dominant and rare clonotypes--with functional annotation--across multiple timepoints, including a case with a single expanded cytotoxic effector-memory T-cell clone (n=35 wells, with elevated NKG7 and CCL5 levels). High-throughput, “mini-bulk” configurations (approx. 100 cells/well) allow broader repertoire screening of ~10,000 cells/plate, detecting thousands of unique beta chains and alpha beta pairs, and facilitating the identification of rare, disease-associated clonotypes missed by bulk or lower-throughput methods.This rapid, cost-effective (<$0.10/cell), single-day workflow supports large-scale translational studies, providing direct access to paired receptor and phenotypic signatures from a variety of samples without reliance on microfluidics platforms or complex barcoding techniques. The technology significantly expands capacity for immunogenomic discovery and functional immunophenotyping, making it suited for biomarker validation, immunotherapy development, and real-time immune monitoring in cancer research.
利益披露 Disclosure
A. Chenchik, Cellecta Employment. T. Liu, Cellecta Employment. D. Hu, Cellecta Employment. K. Paraiso, Cellecta Employment. L. Kobzik, Cellecta Independent Contractor. K. Ghias, Cellecta Employment. P. Diehl, Cellecta Employment.

← 返回 AACR 2026 检索